[HTML][HTML] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - Elsevier
… were randomized to receive blinded maintenance erlotinib 150 mg/day (‘early erlotinib’) or
… open-label erlotinib (‘late erlotinib’); patients who progressed on erlotinib received approved …
… open-label erlotinib (‘late erlotinib’); patients who progressed on erlotinib received approved …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
… The effect of active maintenance therapy on disease progression when introduced
immediately after first-line platinum-doublet chemotherapy has therefore been investigated for …
immediately after first-line platinum-doublet chemotherapy has therefore been investigated for …
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
X Chen, Y Liu, OD Røe, Y Qian, R Guo, L Zhu, Y Yin… - PloS one, 2013 - journals.plos.org
… also benefit from TKI maintenance (this mainly due to the effect of erlotinib in SATURN). As
… first-line maintenance erlotinib versus erlotinib at the time of disease progression in patients …
… first-line maintenance erlotinib versus erlotinib at the time of disease progression in patients …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
J Casal Rubio, JL Firvida-Perez… - Cancer chemotherapy …, 2014 - Springer
… The safety profile of maintenance erlotinib was as expected and manageable. … TTP was
measured from date of first erlotinib dose until disease progression or death due to progression. …
measured from date of first erlotinib dose until disease progression or death due to progression. …
[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
… /IV) NSCLC, whose disease did not progress following four cycles of … maintenance therapy
with either erlotinib 150 mg/day or placebo until unacceptable toxicity or disease progression (…
with either erlotinib 150 mg/day or placebo until unacceptable toxicity or disease progression (…
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
… therapy or delayed therapy to be started at the time of disease progression. An important …
-treated patients at disease progression so as to demonstrate that early maintenance therapy is …
-treated patients at disease progression so as to demonstrate that early maintenance therapy is …
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
N Reguart, AF Cardona, R Rosell - Cancer management and …, 2010 - Taylor & Francis
… Citation68 In this trial, responding patients were also permitted to continue with erlotinib or
placebo until there was disease progression or unacceptable toxicity. The trial did not achieve …
placebo until there was disease progression or unacceptable toxicity. The trial did not achieve …
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
JW Neal - Future Oncology, 2010 - Taylor & Francis
… investigate the effectiveness of maintenance erlotinib treatment until the time of progression,
with the goal of prolonging overall survival and delaying disease progression Citation[19]. …
with the goal of prolonging overall survival and delaying disease progression Citation[19]. …
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Anti-cancer drugs, 2011 - journals.lww.com
… maintenance therapy with administration of 150 mg of erlotinib per day or placebo until disease
progression… The second trial, which implemented bevacizumab/erlotinib as maintenance …
progression… The second trial, which implemented bevacizumab/erlotinib as maintenance …
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer
VJ Muir, S Dhillon - BioDrugs, 2011 - Springer
… ) as part of the run-in phase of the study, were randomized to receive oral erlotinib 150
mg/day or placebo until disease progression, unacceptable toxicity, or death.[5] In addition, …
mg/day or placebo until disease progression, unacceptable toxicity, or death.[5] In addition, …
相关搜索
- lung cancer maintenance erlotinib
- erlotinib maintenance therapy
- role of erlotinib maintenance treatment
- disease progression in patients maintenance erlotinib
- saturn trial maintenance erlotinib
- saturn study maintenance erlotinib
- maintenance erlotinib disease progression nsclc
- maintenance erlotinib cancer progression
- asian patients maintenance erlotinib
- maintenance erlotinib disease progression breast
- maintenance erlotinib resistance
- maintenance erlotinib side effects
- maintenance pembrolizumab disease progression
- maintenance venetoclax disease progression
- maintenance erlotinib disease progression melanoma
- maintenance erlotinib disease progression glioma